Skip to content

Advertisement

Advances in Cancer Immunotherapy

Cancer ImmunotherapyGuest Edited by: Prof. Mauro Castelli1, Prof. Gabriella D’Orazi2 & Dr. Anand Rotte3 

1 - Editor-in-Chief of Journal of Experimental & Clinical Cancer Research
2 - Department of Medical Sciences, University “G. D’Annunzio”, Chieti, Italy
3 - Clinical & Regulatory Affairs, NevroCorp, Redwood City, CA, USA


Drugs acting by stimulating the immune responses have been immensely successful in the treatment of cancer. Several classes of immunotherapeutics including cytokines such as interleukin-2 (IL-2) and interferon-α2b (IFN-α2b), monoclonal antibodies against immune checkpoints, autologous dendritic cells expressing tumor antigen, genetically engineered oncolytic viruses, and T-cells engineered to expressed chimeric antigen receptors (CAR-T cells), have been approved for multiple cancer subtypes, including both solid tumors, as well as hematological cancers. Durable response rates are considered as the greatest advantages of immunotherapy but its success is overshadowed by low response rates. Insufficient immune activation and involvement of multiple immunosuppressive pathways are thought to be the reasons for treatment failure in non-responding patients. To increase the response rates, a combination of immunotherapeutics has been suggested. Research is ongoing to design better and safer combinations by altering dosage or sequence of administration of approved drugs, or by developing new drugs and their combinations.

The purpose of this thematic series, published in Journal of Experimental & Clinical Cancer Research, is to summarize some of the highlights of cancer immunotherapy that may provide new opportunities for personalized anti-cancer therapy as well as presenting challenges on the road to the clinic. This thematic series welcomes both reviews and original research articles - please refer to the journal submission guidelines for the criteria of each article type.

Submission deadline: 31st May 2019

Submit your manuscript here using the online submission system. Please indicate in your covering letter that you would like your manuscript to be considered for the ‘Advances in Cancer Immunotherapy’ thematic series.

  1. Content type: Review

    Immune checkpoint inhibitor therapy has changed clinical practice for patients with different cancers, since these agents have demonstrated a significant improvement of overall survival and are effective in ma...

    Authors: Francesca Di Modugno, Cristina Colosi, Paola Trono, Giuseppe Antonacci, Giancarlo Ruocco and Paola Nisticò

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:117

    Published on:

  2. Content type: Research

    Though immune checkpoint blockade (ICB) against PD-1 has shown success in the treatment of lung cancer, not all patients respond. We have previously shown that adoptive transfer of double negative T (DNT) cell...

    Authors: Linan Fang, Dalam Ly, Si-si Wang, Jong Bok Lee, Hyeonjeong Kang, Hao Xu, Junlin Yao, Ming-sound Tsao, Wei Liu and Li Zhang

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:123

    Published on:

  3. Content type: Review

    Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer patients...

    Authors: Daniela Criscuolo, Francesco Morra, Riccardo Giannella, Roberta Visconti, Aniello Cerrato and Angela Celetti

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:91

    Published on:

  4. Content type: Research

    The muscle invasive form of urothelial bladder cancer (UBC) is a deadly disease. Currently, the therapeutic approach of UBC is mostly based on surgery and standard chemotherapy.

    Authors: Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano and Angela Celetti

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:90

    Published on:

  5. Content type: Review

    PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung c...

    Authors: Xin Wang, Gaochao Guo, Hui Guan, Yang Yu, Jie Lu and Jinming Yu

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:87

    Published on:

  6. Content type: Research

    Despite the increasing progress in targeted and immune based-directed therapies for other solid organ malignancies, currently there is no targeted therapy available for TNBCs. A number of mechanisms have been ...

    Authors: Murugan Kalimutho, Debottam Sinha, Deepak Mittal, Sriganesh Srihari, Devathri Nanayakkara, Shagufta Shafique, Prahlad Raninga, Purba Nag, Kate Parsons and Kum Kum Khanna

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:85

    Published on:

  7. Content type: Research

    Personalized cancer vaccines based on neoantigens have reached the clinical trial stage in melanoma. Different vaccination protocols showed efficacy in preclinical models without a clear indication of the qual...

    Authors: Luigi Aurisicchio, Erika Salvatori, Lucia Lione, Silvio Bandini, Matteo Pallocca, Roberta Maggio, Maurizio Fanciulli, Francesca De Nicola, Frauke Goeman, Gennaro Ciliberto, Antonella Conforti, Laura Luberto and Fabio Palombo

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:78

    Published on:

  8. Content type: Research

    Pancreatic ductal adenocarcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint blockade therapy, including anti-PD-1 and anti-PD-L1, is a new therapeutic strategy for cancer...

    Authors: Ping Fan, Jingyuan Zhao, Zibo Meng, Heyu Wu, Bo Wang, Heshui Wu and Xin Jin

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:47

    Published on:

  9. Content type: Research

    Human microsatellite-stable (MSS) colorectal cancers (CRCs) are immunologically “cold” tumour subtypes characterized by reduced immune cytotoxicity. The molecular linkages between immune-resistance and human M...

    Authors: Guido Giordano, Pietro Parcesepe, Mario Rosario D’Andrea, Luigi Coppola, Tania Di Raimo, Andrea Remo, Erminia Manfrin, Claudia Fiorini, Aldo Scarpa, Carla Azzurra Amoreo, Fabiana Conciatori, Michele Milella, Francesca Pia Caruso, Luigi Cerulo, Almudena Porras and Massimo Pancione

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:28

    Published on:

  10. Content type: Research

    Triple negative breast cancer (TNBC) is an aggressive malignancy with poor prognosis, in part because of the current lack of any approved molecularly targeted therapy. We evaluated various combinations of thre...

    Authors: Elaine Reguera-Nuñez, Ping Xu, Annabelle Chow, Shan Man, Frank Hilberg and Robert S. Kerbel

    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:16

    Published on:

  11. Content type: Research

    Abundant evidence shows that triple-negative breast cancer (TNBC) is heterogeneous, and many efforts have been devoted to identifying TNBC subtypes on the basis of genomic profiling. However, few studies have ...

    Authors: Yin He, Zehang Jiang, Cai Chen and Xiaosheng Wang

    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:327

    Published on:

  12. Content type: Commentary

    This commentary wishes to highlight the 2018 Nobel Prize in Medicine awarded to two cancer immunotherapy scientists, Prof James Allison and Prof Tasuku Honjo, for their discovery on unleashing the body’s immun...

    Authors: Anand Rotte, Gabriella D’Orazi and Madhuri Bhandaru

    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:262

    Published on: